Medical Oncology

Hematologic Malignancies   

Questions discussed in this category

E.g., for a patient with myeloma, s/p induction therapy, and high-dose chemotherapy, followed by autologous rescue with inappropriate antibody respons...

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

If there are light chain deposits on the kidney, is that conclusive of MGRS?

How do you counsel patients and caregivers? Do you prescribe medications (''appetite stimulants'') with the goal to improve appetite even if they do n...

Triplet v. Quadruplet? Do you opt for VRd, DaraRD, CyBorD, Dara-RVd or another regimen?  How would this change for a patient with high risk cyt...

This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...

Are there characteristics which could help identify whether a follicular lymphoma might behave more indolently vs aggressively and inform treatment se...

How frequently and what type of testing/sample are you performing MRD assessment? Does your approach differ between transplant-eligible and transplan...

Are you more inclined to use non cytotoxic regimens such as R2 or PI3K inhibitors?

Do you utilize rituximab or any other specific management strategies?

What XRT dose do you use? Does the location of the disease (e.g., mediastinum) affect your decision when taking toxicity into account? would you offer...

Would a negative NGS eliminate the possibility of MDS? Is bone marrow biopsy indicated in a patient with pancytopenia with a negative NGS panel?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion? 

Several patients with inability to access oral cyclophosphamide or lenalidomide, have attempted assistance and grants to no avail.

Given recent retrospective study showing potential lack of benefit with bortezomib-based maintenance therapy (Bumma et al., PMID 37021929).High-risk a...

Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...

Do next generation sequencing results influence diagnostic and therapeutic decisions for patients with MDS?

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?

Please specify how your institution is allocating resources now or will be soon.

Assuming there is clear laboratory and/or imaging evidence of disease progression, and assuming FISH data is already available from a prior biopsy, do...

Patient with stable disease on maintenance therapy with lenalidomide and dexamethasone

240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...

In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytore...

Do you worry about their marrow reserve and response to neulasta in terms of lymphocytosis and decreased ANC response?

What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

E.g. in a patient with tenuous cardiac function, would starting treatment several weeks earlier potentially improve outcomes?

The patient has also acquired mutations in BCR-ABL, namely p.Met244Val, (c.730A>G); 3.7%, which may confer resistance, and p.Phe359Cys, (c.1076T>...

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...

This is a recently described entity with poor prognosis, so even with a CR after RCHOPx6 cycles, is your bias to push for ISRT due to EBV being poor p...

It is understood that the trial's experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about rea...

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?

Does your treatment approach differ from Waldenstrom's Macroglobulinemia? Does the presence/absence of a MYD88 L265P and/or CXCR4 mutation change you...

If tolerated through Cycle #1, how aggressively do you try to titrate the selinexor dose up toward 100mg weekly or 80mg twice-weekly? And does your a...

How do you generally think about sequencing treatment among available options? Would your choice be affected by a patient's eligibility for transplan...

Do you have a certain immunoglobulin level which you would use to determine this?

If so, how do you incorporate GCSF into treatment of these patients?

What VAF burden would be considered significant prognostically or for treatment decisions?

How much weight do you give to a hgb/hct threshold versus symptoms?

Are there agents (eg. bendamustine) or modalities to avoid? Does washout times prior to collection vary between modalities?

Please specify your approach in elective and emergency surgical situations

E.g. a patient with monoclonal protein with mild light chain ratio elevation. Do we need to get a BM biopsy in all such patients?

In this case, the patient had received daratumumab/lenalidomide/dexamethasone as part of a cooperative group trial. Would you say that the patient had...

Does your answer change based on clinical or molecular risk factors, and if so how? Does your answer change if MRD status after induction is unknown?

Infection is not part of the criteria for starting treatment both in UpToDate and in NCCN guidelines. 

How do you determine whether to add intrathecal chemotherapy in patients with +CSF? Would your approach change for primary vs secondary CNS lymphoma?

iPET2 and iPET4 showed Deauville 5 response. CT biopsy after 4 cycles was negative. Patient is currently scheduled for 2 additional cycles of ABVD.

How do you assess if a patient may be a candidate for CAR-T cell therapy?

When is this discussed? What are the common/less common toxicities you advise patients on? Are there best practices for coordination with referring on...

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

Does the safety profile impact your choice significantly? Does your first choice vary by disease histology?

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

My experience has been that patients can be neurologically devastated years out from WBRT. In Medical Oncology practice at my institution, we do not r...

We know the longer we expose patients to lenalidomide, the harder collection will be. Would you collect now or switch to an alternative regimen to ach...

How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...

Peripheral blood flow shows prominent NK cell population but marrow aspiration/bx shows normocellular marrow with trilineage hematopoiesis. 

Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?

Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...

i.e. treatment-refractory PV, prior to progression to PMF or AML

Are the early results of CASSIOPEIA (Abst 8003) from ASCO 2019 practice changing? What about the GRIFFIN results in 2020?

Do you modify the aspirin dose based off the lenalidomide dose? Do you ever use higher dose aspirin in lieu of an anticoagulant? The NCCN guidelines s...

For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...

If the patient cannot tolerate methotrexate or further chemotherapy, how effective is radiation therapy (e.g. WBRT) in rendering the patient disease-f...

After 3-4 cycles of RVD, would you automatically take the patient to transplant if he has achieved at least a partial response, or is there any benefi...

Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...

Can you expand on this by sharing exactly what this routine workup should include? What additional tests outside of evaluating for POEMS and amyloidos...

Does this data change your preferred first line treatment regimens when considering other options such as mAb combos, cytotoxic chemotherapy?

Is the non-inferiority margin of 1.429 sufficient, how was this selected? Is the open label (rather than blinded) study design of any concern? Is th...

Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?

In the case of subtle single lineage dysplasia with normal cytogenetics, do you routinely perform NGS testing for CHIP-type clonal mutations? Do you ...

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

If yes would you delay initiation of antineoplastic therapy to allow time for the vaccine to start acting?

Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients  

How does age play a role in this decision?  If you do intensify therapy, how do you explain the negative results of CALGB/Alliance 50303?

How is this impacted by patient features, cytogenetics/disease biology, depth of response, or other factors? What would compel you to continue 3 drugs...

How do you factor in patient age, frailty, patients with underlying organ dysfunction, or other clinical features? Do you still consider CyBorD or R...

In your experience, do certain regimens have more cumulative toxicity, financial impact, or patient convenience factors?

If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...

Are there scenarios where you would use a higher dose of lenalidomide in a novel doublet or triplet (eg. relapse on lenalidomide maintenance)?

Would you change your radiation therapy treatment dose or volume if you needed to treat a chloroma? If a patient had a separate cancer (e.g. skin canc...

When would you consider utilizing autologous SCT in those with a PR or SD? Is there a potential role for BCMA-directed CAR-T or bispecific therapy in...

Would you use ALK inhibitors such as crizotinib based on recent phase II data? Are there any research efforts to combine ALK inhibitors with current ...

How do you distinguish this entity from other plasma cell disorders (eg. MGUS, MM, etc.)?   Review of literature suggests that most of these pa...

Are there any subsets of patients that you're more inclined to offer maintenance?

What regimens would you consider combining it with? Any specific combinations to avoid or special considerations?

Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?

Is Ommaya placement with CNS-directed therapy preferred to intrathecal or cranial irradiation? How do you interweave this therapy with systemic therap...

Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?

Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

Would you use R-CHOP or a more intensive chemotherapy regimen?  Would you consolidate with radiation therapy after 3 cycles or use systemic thera...

The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2,  the clinical staging/risk classification did not include ESR, b...

Does your recommendation differ between autologous and allogeneic transplants? Does your recommendation differ in allogeneic transplant recipients wh...

Would you offer refractory doses (40-50 Gy) to the RPnodes and send for splenectomy? Or would you offer refractory doses to both RP nodes and spleen?&...

Does your management change based on the type of end-organ involvement at the time of diagnosis? Are there any reports of CNS involvement with non-se...

Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?

Do you use specific tools or take into account certain factors when considering treatment options for older adults?

Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?

If so, what is your time threshold for when you'll start PCP prophylaxis--when you anticipate steroid courses greater than 1 week? 1 month? 3 months?&...

An otherwise healthy patient with spleen only diffuse large B cell lymphoma with mild spleenomegaly, Spleenectomy plus Rchop or Rchop plus RT? 

Can results from emerging AML data be extrapolated to high risk MDS populations? Is there data to guide the choice of continuing the HMA in combinati...

Bulky adenopathy compressed bilateral ureters, CrCl < 30, post stent placement, but renal function has plateaued

Is there any data justifying the use of systemic therapy over localized therapy (e.g. radiation or surgery) in this situation prior to a progression e...

Do you only give intrathecal chemotherapy or systemic therapy?

What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without ritu...

For example, for joing replacement surgery? Do you hold the revlimid for certain about of time before and after?

Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?

Would your approach change based on the type of reaction (eg. Stevens-Johnson syndrome vs DRESS)? How would you address maintenance (if any) post-tra...

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, ...

To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Dar...

Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first? Would the type or degree of organ involv...

Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup? In whom should treatment b...

Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...

Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...

Would you still proceed to high-dose therapy and autologous SCT? Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...

Specifically, do you utilize 3 cycles of chemo with ISRT or 6 cycles? Do you use R-EPOCH or R-CHOP in these cases?

For instance, do you ever start with dasatinib 50 mg daily?  Are there any titration schedules that you follow?

Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM p...

e.g. mixed indolent/aggressive NHL, mixed NHL/HL? Is there a definitive way to discern composite from transformation? NCCN does not list recommendatio...

if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?

How would you handle high risk features (eg double hit) with the limitations of dialysis?

Would you give 3 cycles of RCHOP followed by consolidative IFRT or 6 cycles of R-mini CHOP? Is there a role for 3 cycles of R-mini CHOP followed by IF...

Thrombosis was ruled out and no etiology was found.  Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...

Some specific questions: Would you recommend repeat biopsy to confirm residual disease? How would your recommendations vary if the patient had pre...

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

NCCN does not list any preferences for the TKIs in their guidelines.

I.e., Can day 2 Rituximab (RCHOP) or day 6 Rituximab (DA-EPOCH, Hyper CVAD) be given? Or should only Day 1 Rituximab be used with chemoimmunotherapy i...

Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the ad...

Since ECHELON-1 trial showed an improvement in PFS (but not OS), are there any situations where you would replace bleomycin with brentuximab...

For example - Would you offer tandem transplantation in a young, fit patient in a CR after first transplant, but with MRD detectable?

Would you follow an algorithm such as the one proposed by Hall et al? How do you decide between intrathecal chemotherapy vs systemic therapy with HD-...

FDA package insert lists posaconazole as strong cyp3A4 inhibitor and states to consider other therapies.

Does presenting total white blood cell count affect your decision? Does myeloid subtype affect your decision? 

How might your decision change if the patient had a suitable 10/10 donor? How about if the patient had a targetable molecular mutation such as IDH2?

Although the MMR vaccine is contraindicated in immunosuppressed patients on anticancer treatment according to CDC/ACIP and IDSA guidelines, data on sa...

Given the recent results presented from the Griffin trial, would you choose a daratumumab-based regimen (eg. D-VRd) over other salvage options (V...

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?

Has the recent data presented at ASH affected your choice of regimen? Would your choice differ between transplant-eligible and transplant-ineligible ...

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...

Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?

Specifically, what regimen would you choose in a patient with new renal failure but not requiring dialysis?

What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?

If a patient obtains a PR or less to front line cladribine, what factors help you chose between a second course of cladribine, an alternative pur...

When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for ...

Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance? Are there situations where you would c...

Are you routinely using letermovir as CMV prophylaxis in high-risk patients? Any special considerations with its use versus other antiviral agents? ...

Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?

Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?

Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all...

Could one make a case for addition of Rituxinab frontline to increase the chances of a complete remission and even maybe achieve MRD-negative status ?

Does it differ from the treatment of other relapsed peripheral T-cell lymphomas? Are there any clinical trials or case series focused on SPTCL? Is t...

Technically, you can have up to 55% of larger cells circulating and still be called CLL.

Once you decide to begin treatment, any special precautions you would use for protein levels starting that high.

Assuming that the involved area is too widespread for RT. Would you try single agent rituximab first? Or obinutuzumab? What if rituximab alone gave on...

The recent NEJM phase II trial looked at a small cohort of 24 patients and show...

the MZL was untreated in the past prior to transformation. Do these patients have a higher risk of recurrence post CR as opposed to patients with de ...

Do you follow treatment guidelines for indolent lymphoma or CLL? How do you get 17p testing on someone with only lymphadenopathy?

Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to g...

Even though Venetoclax is not FDA-approved yet, assuming you can get it off label? 1. Gemtuzumab: What dose/schedule and which HMA? 2. Venetoclax: W...

My practice had always been to transfuse for plts < 10, but the recent ASCO guideline change suggests  that in the post-autoSCT setting it is ...

If filgrastim, how many days would you give? Pegfilgrastim is often not covered by payers if given less than 14 days before chemotherapy.

The patient has no medical problems and no history of leukemia/MDS. Biopsy of the filum terminale and arachnoid confirmed a myeloid sarcoma and MRI sh...

Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?

In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a...

For example, how significant does the M protein have to increase for you to begin a conversation about new therapy?

Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?

If a patient will receive a total of 4 cycles ABVD and has a CR by PET/CT after cycle 2, can RT be omitted to non-bulky sites to avoid toxicity?

Specifically I am thinking if a PET scan shows complete response, would it be reasonable to stop bleomycin and continue AVD?

Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...

Specifically when given as a single agent. Any role for G-CSF?

PET/CT/bone marrow biopsy negative for evidence of distant disease. Following 4 cycles of combination chemotherapy with no evidence of progressive dis...

At what point is the neuropathy a contraindication to further bortezomib therapy?

Although bendamustine + rituximab is a standard option for advanced follicular lymphoma when treatment is required, does the regimen rituximab + lenal...

Specifically, can you rechallenge after the effusion has resolved (e.g. therapeutic thoracentesis)? If so, how long do you wait to rechallenge (especi...

Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?

If so, do you use antivirals and/or antibiotics? Does it matter if the patient has mantle cell lymphoma, CLL, or Waldenstrom's macroglobulinemia?

Specifically, do you just wait for count recovery? Do you check for morphologic or molecular remission at all during this time?

Specifically, is there still a role for dd RCHOP followed by ICE, or do you recommend DA-R-EPOCH for all patients?

NCCN guidelines suggest XRT as standard of care for this stage of disease. However, occasionally patients have their tumors completely excised when un...

What is the utility of repeating FISH studies to evaluate for clonal evolution if FISH studies were done at diagnosis?

If a patient with stage I, low grade follicular lymphoma achieves a complete response after rituxan and treanda is there any role for consolidative ra...

Papers discussed in this category

J. Clin. Oncol., 2014-04-10

J. Clin. Oncol., 2013-11-10

Oncology (Williston Park, N.Y.), 2012-12

N. Engl. J. Med., 2010-08-12

The New England journal of medicine, 2013-04-11

Cancer, 2004-08-15

Br. J. Haematol., 2003-11-01

Br. J. Haematol., 1998-08-01

Cancer, 1990-11-15

Radiother Oncol, 1990-01-01

The New England journal of medicine, 2010-06-17

Blood, 2014-01-23

The New England journal of medicine, 2010-06-17

The New England journal of medicine, 2015-12-17

Blood, 2022 Jul 14

Leukemia, 2021 Apr 27

J Am Coll Cardiol, 2019 Oct 01

British journal of haematology, 2017-11

Medical and pediatric oncology, 1981

JAMA, 2013-04-03

Haematologica, 2016-12-01

Clin Pharmacokinet, 2012-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-10

J Clin Oncol, 2010 Oct 10

J. Natl. Cancer Inst., 2011 Oct 21

The Lancet. Oncology, 2016-08

J. Clin. Oncol., 2010 May 03

Blood, 2016-10-13

The Lancet. Oncology, 2014-11

The New England journal of medicine, 2016-06-23

Blood, 2013-12-19

Cancer, 2004-05-15

Blood, 2016-12-22

Blood, 2014 Feb 05

N. Engl. J. Med., 2015-04-23

Leuk. Lymphoma, 2007-09-01

The New England journal of medicine, 2015-08-13

N. Engl. J. Med., 2018-01-25

British journal of haematology, 2004-04



Br. J. Haematol., 2017 Nov 21

American journal of hematology, 2016-05

Blood, 2018-06-21

Nature, 2019-06

Leukemia, 2019-02

The Lancet. Oncology, 2009-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Cancer, 2011-06-15

American journal of hematology, 2009-09

Cancer, 2010-08-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-15

Lancet, 2009 Sep 18

Lancet, 2021 Mar 06

Blood, 2013-11-14

J. Clin. Oncol., 2016 Jan 25

Leukemia, 2016-02

The Lancet. Oncology, 2018-02

The Lancet. Oncology, 2010-01

The New England journal of medicine, 2014-09-04

The New England journal of medicine, 2019-05-30

Lancet (London, England), 2017-02-04

The New England journal of medicine, 2018-02-08

Blood, 2018-01-18

N Engl J Med,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-05

British journal of haematology, 2018-10

Blood Adv,

The New England journal of medicine, 2017-12-28

JAMA oncology, 2018-02-01



Blood, 1998-09-01

American journal of hematology, 2017-01

Avicenna J Med, 2017 Jul-Sep

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

The New England journal of medicine, 2016-11-24

The Lancet. Haematology, 2018-01


Blood, 2014-05-22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

J. Clin. Oncol.,

Lancet (London, England), 2018-02-17

Fertil. Steril., 2013 Sep 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jun 05

Leukemia, 2018-08

The New England journal of medicine, 2015-10-29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-10

J. Clin. Oncol., 2018 Jul 05

Lancet (London, England), 2019-01-19

Blood, 2017-03-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

J. Clin. Oncol., 2009 Oct 05

Ann. Oncol.,

Cancer Res., 2010 Feb 02

Haematologica, 2019-04

Dig Liver Dis, 2013 Jun 28

Am. J. Clin. Oncol.,

The New England journal of medicine, 2017-04-06

Haematologica, 2011 Nov 04

Blood, 2018 Sep 04

Clin. Cancer Res., 2011 Feb 16

J. Clin. Oncol., 2013 Oct 21

Blood Adv,

Bone marrow transplantation, 2018-07

Blood, 2017-02-02

The Lancet. Haematology, 2016-05

The Lancet. Haematology, 2017-11

Eur J Haematol, 2023 Mar 27

Blood, 2016 Mar 21

Lancet Oncol, 2020 Aug 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

N. Engl. J. Med.,

Blood, 2018-03-15

Cancer, 2015-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-01

Neuro-oncology, 2009-04

Lancet Haematol, 2015 Jun 03

Radiother Oncol, 2011 Jun 12

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02

Haematologica, 2016 Jun 16

Blood, 2015-11-19

Blood, 2017 Apr 19

Blood, 2021 Jul 13

The New England journal of medicine, 2017-08-03

Lancet, 2012 Apr 05

Haematologica, 2018 Aug 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Leukemia, 2014-03

Cancer, 2014-12-01

Blood, 2019-04-04

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Haematologica, 2017 Sep 21

British journal of haematology, 2015-12

Blood Adv,

The Lancet. Oncology, 2014-03

The New England journal of medicine, 2012-05-10

Leukemia, 2019-01

Blood, 2017 Aug 3

J. Clin. Oncol., 2019 Sep 10

N Engl J Med, 2021 Dec 11


American journal of hematology, 2018-08

Am. J. Hematol., 2019 Nov 19

Ann. Allergy Asthma Immunol., 2019 Aug 07

Clin Lymphoma Myeloma Leuk,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

N. Engl. J. Med.,

Nature medicine, 2015-02

Clin Lymphoma Myeloma Leuk, 2017 Jun 21

The New England journal of medicine, 2007-01-25

Haematologica, 2020

Nature, 2019-03

Blood, 2018 May 02

Leuk Lymphoma, 2019 Dec 26

Blood, 2016-07-28

Blood advances, 2016-12-27

Cancer, 2016-10

Blood, 2017-08-31

Biol. Blood Marrow Transplant., 2019 Aug 22

Leukemia & lymphoma, 2017-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jul 24

Lancet Oncol., 2014-04-01

Clin Lymphoma Myeloma Leuk, 2020 Mar 06

J Hematol Oncol, 2018 Jan 16

Blood, 2017-07-06

The Lancet. Oncology, 2019-06

Leukemia, 2016-04

Leukemia & lymphoma, 2018-07


Blood, 2016 Dec 27

Lancet, 2019 Jun 03


Blood, 2018 Apr 5

N Engl J Med,

Blood, 2019-01-24

JAMA network open, 2018-11-02

The New England journal of medicine, 2018-03-22

Lancet Oncol, 2016 May 20

Lancet Oncol,

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Leuk Lymphoma, 2011 Dec 13

Blood, 2018 Jun 18

The journal of allergy and clinical immunology. In practice, 2017

Therapeutic advances in hematology, 2012-04

J Clin Oncol, 2021 Jan 13

Leukemia, 2020 May 07

Haematologica, 2019 Oct 03

Ann Hematol, 2020 Apr 19

Blood, 2020 Sep 23

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011-03

Blood, 2015 Sep 17

Pediatric blood & cancer, 2017-04

Hematol Oncol, 2017 Oct 30

Lancet Oncol, 2020 Mar 11

American journal of hematology, 2019-04

Lancet Oncol, 2019 Dec 16

N Engl J Med,


Lancet Haematol, 2020 Oct 01

J Clin Oncol, 2013 Nov 12

Blood Adv,

Bone Marrow Transplant, 2019 Oct 01

Front Immunol, 2020 Apr 03

N Engl J Med,

Blood, 2007-01-15


Blood, 2017 Jan 27

Blood, 2021 Mar 08

The New England journal of medicine, 2016-07-14

Practical radiation oncology, 2021 Sep-Oct

Palliative medicine, 2022 Mar 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Mar 28


Blood, 2013-10-24

The Lancet. Oncology, 2011-08

The Lancet. Oncology, 2018-03

J Clin Oncol, 2021 Apr 07

British journal of haematology, 2018-07

J Geriatr Oncol, 2021 Mar 06

Leukemia, 2018 Apr 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27

Blood, 2011-05-05

Haematologica, 2016 Dec 01

Blood Cancer J, 2021 May 12

Leuk Lymphoma, 2019 Nov 18

Blood, 2013-10-03

Leukemia, 2019-09

Blood, 2016-01-21

J Clin Oncol, 2012 Jul 16

Lancet (London, England), 2016-04-09

The Lancet. Oncology, 2019-06

Lancet Oncol,

Ann Oncol, 2021 Mar 18

J Clin Oncol, 2021 Jul 26

Strahlenther Onkol, 2017 Jun 01

Nature communications, 2019-04-23

Blood, 2012 Aug 13

J Clin Oncol, 2020 Apr 16


The Lancet. Oncology, 2019-01


Clin Transl Oncol, 2020 Sep 17

J Assist Reprod Genet, 2020 Jun 02

Lancet Oncol, 2018 Sep 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20

Lancet (London, England), 2010-12-11

Blood, 2012 Apr 04

Clin Lymphoma Myeloma Leuk, 2019 Sep 30

Bone Marrow Transplant, 2018 Jun 08

International journal of radiation oncology, biology, physics, 2019-12-01

The Lancet. Oncology, 2019-01

Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07

Cancer immunology research, 2019-07

Br J Haematol, 2020 Mar 5

Lancet, 2020 Sep 01

Blood Adv,

Int J Radiat Oncol Biol Phys, 2020 May 22

Radiother Oncol, 2021 Dec 7

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Int J Radiat Oncol Biol Phys, 2022 Dec 20

Transplant Cell Ther, 2022 Dec 30

Blood advances, 2020 Jul 28

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26

Blood advances, 2020 Nov 24

Haematologica, 2023 Jun 15

Leukemia, 2023 May 05

J. Clin. Oncol., 2019 Oct 25

N Engl J Med,

The Lancet. Oncology, 2017-09

J Clin Oncol, 2020 Apr 10

The Lancet. Oncology, 2018-07

Blood Cancer J, 2020 Mar 09

JAMA Oncol,

JAMA, 2016-11-15

N Engl J Med,

J Clin Oncol, 2019 Apr 10

J Clin Oncol, 2020 Feb 21

J Clin Oncol, 2020 Oct 06

The Lancet. Oncology, 2021 Oct 13

The Lancet. Haematology, 2023 Sep 11

JCO Oncol Pract, 2020 Aug 21

Mayo Clin Proc,

Neurol Sci, 2021 Sep 16

Journal of clinical pathology, 2017-09

Leukemia, 2018-06

Haematologica, 2021 Jun 01

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017-05

Transplant Proc,

The New England journal of medicine, 2015-11-05

Haematologica, 2018 May 24


Leukemia, 2011 Jul 01

Haematologica, 2019 Sep 19

Blood, 2017 Aug 17

Blood, 2015 May 28

Clin Lymphoma Myeloma Leuk, 2020 Mar 07

Clin Lymphoma Myeloma Leuk, 2021 Jul 18

Blood Cancer J, 2021 Jan 11

Blood cancer journal, 2018-06-12

JAMA Oncol,

British journal of haematology, 2014-06

International journal of radiation oncology, biology, physics, 2019-06-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Blood, 2018-07-05



J Clin Oncol, 2021 Jun 25

Blood Cancer J, 2020 May 11

Lancet Oncol, 2020 Oct 29

The New England journal of medicine, 2019-06-06

Leukemia, 2022 Jan 01

Blood Adv,

Blood, 2018 Dec 13

Pediatric blood & cancer, 2007-02

Blood, 2021 Nov 15

Lancet Haematol, 2019 Sep 16

Blood, 2011-09-15

Haematologica, 2011 Dec 01

Cancer Chemother Pharmacol, 2016 Jun 10

Clin Cancer Res, 2020 Aug 17

J Clin Oncol, 2016 Feb 29

Lancet Haematol, 2016 Dec 05

Lancet Oncol, 2022 Jan 21

N Engl J Med,

American journal of hematology, 2019-11

J Clin Oncol, 2011 Jan 31

J Natl Compr Canc Netw,

Hematology (Amsterdam, Netherlands), 2019-12

J Clin Oncol, 2021 Aug 13

Blood Adv, 2021 Sep 01

Blood, 2015-03-26

Clin Lymphoma Myeloma Leuk, 2019 Oct 09

JCO Oncol Pract, 2019 Nov 25

Lancet Haematol,

Leukemia, 2020 Jul 21

Haematologica, 2015-01

Blood advances, 2019-01-22

Am J Hematol, 2019 Apr 04

N Engl J Med,

Clin Lymphoma Myeloma Leuk, 2020 Jul 29

Lancet Oncol, 2014 Oct 26

Blood cancer journal, 2016-07-29

Leukemia, 2022 Apr 11

Clin Infect Dis,

Blood, 2008-02-15

The Lancet. Haematology, 2018-12

Lancet Oncol, 2020 Jun 05

J Clin Oncol, 2019 Nov 06

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04

Pediatr Blood Cancer, 2019 Jul 31

Future Oncol, 2021 Jan 11

N Engl J Med, 2022 Jun 03

J Clin Oncol, 2021 Mar 19

N Engl J Med, 2022 Jun 05

N Engl J Med, 2022 Jun 05

BMC Cancer, 2010 Aug 09

The American journal of medicine, 1997-01

Blood, 2019 Jul 25

N Engl J Med, 2017 Jun 1

Leukemia, 2021 Apr 28

Haematologica, 2019 Aug 14


Journal of hospital medicine, 2018-08-01

Front Oncol, 2022 Mar 09

BMJ Support Palliat Care, 2022 Jul 08

Nutr Cancer, 2019 Oct 12

N Engl J Med,

American journal of hematology, 2019-05

Amyloid, 2017 Apr 23

Leukemia, 2015 Oct 07

British journal of haematology, 2017-10

Blood Adv,

Blood Cancer J, 2018 May 24

Amyloid, 2019 Jan 20

Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11

Proc Natl Acad Sci U S A, 2019 Apr 15

N Engl J Med,

International journal of radiation oncology, biology, physics, 2018-04-01

Blood Cancer J, 2022 Sep 14

The Lancet. Oncology, 2018-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-01



N Engl J Med,

Ann Oncol, 2009 Jul 01

Blood, 2010 Jul 21

The Lancet. Haematology, 2019-03

J Clin Oncol, 2021 Dec 02

Lupus, 2019 Jun 19

Ann Rheum Dis, 2011 Nov 09

Blood Adv, 2022 Sep 13

Urology, 1982-09

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-03

Clin Infect Dis, 2005 Jan 21

Pediatr Transplant, 2014 Sep 08

J Clin Oncol, 2021 Apr 30

Pediatr Infect Dis J, 2014 Nov

Bone Marrow Transplant, 2006 Mar

Blood, 2006-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01

The Lancet. Oncology, 2015-10

N Engl J Med, 2013 Jul 11

Blood, 2012 Jun 19

Blood, 2017-09-28

Blood, 2019-04-11

N Engl J Med, 2022 Dec 11

Br J Haematol, 2021 Aug 15

Blood, 2022 Dec 08

Transpl Infect Dis, 2015 Sep 26

Clin Lymphoma Myeloma Leuk, 2021 Feb 07

Lancet, 1994 Apr 30

Blood Adv, 2022 Jun 14

J Clin Oncol, 2021 Oct 07

J Clin Oncol, 2022 Jun 04

J Clin Oncol, 2022 Oct 21

J Clin Pharmacol, 2021 Jul 16

Leukemia, 2019-03

Journal of the American Society of Nephrology : JASN, 2007-03

Lancet Haematol, 2019 Mar 11

Blood Cancer J, 2022 Sep 02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-01

Blood Adv, 2021 Aug 24

Blood, 2014 Apr 16

J Clin Oncol, 2018 Mar 02

N Engl J Med, 2009 Jan 07

Front Oncol, 2020 Jul 16

Leukemia, 2021 Jun 26

Haematologica, 2021 Nov 01

Blood, 2022 Mar 03

Cancer, 2021 Jun 28

Haematologica, 2009-01

Leukemia, 2022 Feb 21

Blood, 2020 Jul 09

Leukemia, 2022 Dec 03

Hered Cancer Clin Pract, 2021 Apr 01

Cancer cell, 2017-06-12

J Neurooncol, 2022 Jun 20

Blood, 2004-09-15

J Clin Oncol, 2015 Dec 07

Lancet Haematol, 2019 Jul 18

Lancet Haematol, 2019 Jul 18

Br J Haematol, 2021 Jun 10

Lancet Oncol, 2022 Jul 12

Journal of the National Cancer Institute, 2016-06

Pediatrics, 2014 Feb 02

N. Engl. J. Med.,

The Journal of urology, 2018-12

N. Engl. J. Med.,

Lancet Oncol., 2014 Feb 18

NEJM Evidence, 2022 Jun 1

Br J Cancer, 2014 Apr 15

Cancer, 2011-06-15

Eur J Cancer, 2017 Nov 28

N. Engl. J. Med., 2019 Sep 28

Lancet Oncol, 2021 Jan 18

J Clin Oncol, 2021 Apr 19

J Clin Oncol, 2003 Jul 01

JAMA, 2019 Apr 16

Head Neck, 2016 Mar 29

The Lancet. Oncology, 2017-05

Lancet, 2021 Jun 24

N Engl J Med, 2023 Jun 05

N Engl J Med, 2023 Feb 10

Lancet Oncol, 2021 Dec 03

Lancet, 2021 Jun 04

Blood, 2022 Oct 20

J Clin Oncol, 2017 Jan 17

Lancet Oncol, 2021 Nov 11

N Engl J Med, 2023 Jun 05

Br J Haematol, 2023 Jun 07

J Clin Oncol, 2022 May 23

Blood Cancer J, 2022 Jan 31

Experimental hematology & oncology, 2022 Feb 28

J Clin Oncol, 2023 May 16

Blood, 2013-08-08

British journal of haematology, 2016-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-10

Journal of the National Cancer Institute, 2013-08-21

Journal of the National Cancer Institute, 2018-01-01

JAMA oncology, 2021 May 01

Antioxidants & redox signaling, 2020 Aug 07

Journal of experimental & clinical cancer research : CR, 2020 Oct 07

BMJ (Clinical research ed.), 2000 Nov 04

Blood advances, 2020 Dec 08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Dec 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Apr 04

Lancet (London, England), 2023 Jun 10

J Hematol Oncol, 2022 Mar 26

Blood advances, 2022 May 10

The Lancet. Haematology, 2023 Sep 27

The Lancet. Oncology, 2011 Dec 13

American journal of hematology, 2022 Jul 05

Blood advances, 2023 Oct 24

Blood, 2018 Aug 14

American journal of hematology, 2016-09

Blood, 2017 Jun 13

Haematologica, 2013-01

The Lancet. Haematology, 2015 May 06

European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06

Mayo Clinic proceedings, 2017-06